NEW YORK, NY / ACCESSWIRE / September 20, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
L Brands, Inc. (LB)
Class Period: May 31, 2018 to November 19, 2018
Lead Plaintiff Deadline: September 23, 2019
The lawsuit alleges L Brands, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (a) the Victoria's Secret and PINK businesses were having a material adverse effect on the Company's cash flow, liquidity and debt levels; (b) Defendants lacked a reasonable basis for their positive statements about the ability of the Company to sustain its dividend; (c) the MD&A disclosures in filings L Brands made with the SEC were materially false and misleading; (d) the risk factor disclosures in filings L Brands made with the SEC were materially false and misleading; (e) the representations about L Brands' disclosure controls in filings the Company made with the SEC were materially false and misleading; (f) the certifications issued by Defendants Wexner and Burgdoerfer on L Brands disclosure controls were materially false and misleading; and (g) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about L Brands' then-current business operations and future financial
Learn about your recoverable losses in LB: http://www.kleinstocklaw.com/pslra-1/l-brands-inc-loss-submission-form?id=3615&from=1
Karyopharm Therapeutics Inc (KPTI)
Class Period: on behalf of shareholders who: (i) purchased shares of Karyopharm's securities between March 2, 2017 and February 22, 2019, inclusive (ii) purchased Karyopharm shares in or traceable to the Company's public offering of common stock conducted on or around April 28, 2017; or (iii) purchased Karyopharm shares in or traceable to the Company's public offering of common stock conducted on or around May 7, 2018.
Lead Plaintiff Deadline: September 23, 2019
The lawsuit alleges that Karyopharm Therapeutics Inc made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile," and assured investors that it was "well tolerated" by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
Learn about your recoverable losses in KPTI: http://www.kleinstocklaw.com/pslra-1/karyopharm-therapeutics-inc-loss-submission-form?id=3615&from=1
Pluralsight, Inc. (PS)
Class Period: August 2, 2018 to July 31, 2019
Lead Plaintiff Deadline: October 15, 2019
According to the filed complaint, the Company failed to disclose that Pluralsight was experiencing substantial delays in hiring and properly training the salesforce necessary to meet its lofty billing projections. In addition, the Company knew at the time of the March 2019 secondary public offering ("SPO") that it was behind schedule onboarding new sales representatives, which was hurting the Company's sales execution and preventing Pluralsight from meeting its high growth projections. Instead of disclosing such facts at the time of the SPO, and to cash-out at inflated prices, Defendants intentionally obscured and omitted this pertinent information from investors.
Learn about your recoverable losses in PS: http://www.kleinstocklaw.com/pslra-1/pluralsight-inc-loss-submission-form?id=3615&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: